MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function

NCT ID: NCT02050815

Last Updated: 2020-09-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2016-08-26

Brief Summary

This study is a phase I, multi-center, open-label, single oral dose, parallel group study to assess the PK and safety of MEK162 in subjects with impaired hepatic function and healthy subjects with normal hepatic function. Subjects will be assigned by hepatic function defined by elevation of serum total bilirubin and serum AST as determined at the screening and baseline visits. The study population will be healthy male and postmenopausal or sterile female subjects who meet all of the inclusion and none of the exclusion criteria. A minimum of 24 evaluable subjects (6 subjects per group) will be enrolled. The groups are: Group 1-healthy volunteers, Group 2-Mild hepatic impairment, Group 3-Moderate hepatic impairment and Group 4-Severe hepatic impairment. Once approved for enrollment, participants will be confined to the facility for 5 days, given a single dose of MEK162 and monitored for safety assessments, labs and PK will be assessed.

Conditions

Hepatic Impairment

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MEK162

A minimum of 24 subjects (6 subjects per group) will be enrolled. Enrollment into Group 1 (control group with normal hepatic function) should be similar to the enrollment into Group 2, 3 and 4 with respect to age, gender, and body weight. Enrollment into Group 1 will remain open until the enrollment into the mild, moderate, and severe impairment groups are complete with matching controls for comparison. Serum level of total bilirubin and AST will be used to determine which group the hepatic impaired patient will be allocated l. Dosing of the different treatment groups will be staggered. Initially, 6 subjects in Group 1 (normal hepatic function) and 6 subjects in Group 2 will receive a single oral dose of MEK162 on Day 1.

Group Type: EXPERIMENTAL

MEK162

Intervention Type: DRUG

Interventions

MEK162

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written informed consent prior to any screening procedures
• Male or female (postmenopausal or sterilized)
• Subject body weight at least 45 kg and a body mass index (BMI) in the range of 18 to 35.0 kg/m2
• Subjects with normal hepatic function must have total bilirubin ≤ upper limit of normal (≤ ULN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and alkaline phosphatase (AP) ≤ ULN, serum creatinine ≤ ULN, serum amylase and lipase ≤ ULN

• Absolute neutrophil count (ANC) > 1000 cell/mm3
• Hb > 9 mg/dl,
• Platelet count > 30,000/mm3
• Serum creatinine ≤ 1.8 mg/dl
• Otherwise considered healthy and free of significant medical disorders unrelated to the subject's hepatic disorder

Exclusion Criteria

• Women of child-bearing potential
• Pregnant or nursing (lactating) women
• Subjects with impaired cardiovascular function or clinically significant cardiovascular diseases
• Uncontrolled arterial hypertension despite medical treatment
• History or current evidence of retinal vein occlusion (RVO) or current risk factors of RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes),
• History of Gilbert's syndrome
• Immuno-compromised subjects (including known history/seropositivity of HIV)
• Any surgical or medical condition (other than hepatic impairment) or receiving any pharmacological treatment which might significantly alter the absorption or metabolism of drugs or which may jeopardize the subject in case of participation in the study
• Antecedent of malignancy with the following exceptions: adequately treated basal cell or squamous cell carcinoma of the skin
• Subjects who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
• Subjects who have undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
• History of clinically significant drug allergy
• Prior therapy with a MEK-inhibitor
• Use of an investigational drug within 30 days of screening
• Current smoker or has used tobacco products or products containing nicotine within 7 days prior to dosing of study drug
• Consumption of alcohol within 3 days prior to dosing or during the study

• Clinical evidence of liver disease or liver injury as indicated by abnormal liver function tests such as ALT, AST, GGT, alkaline phosphatase, or serum bilirubin. ALT and AST beyond the normal range before inclusion Presence of impaired renal function as indicated by abnormal creatinine (creatinine clearance < 80 mL/min) values and/or serum creatinine ≥1.8 mg/dL- A positive Hepatitis B or Hepatitis C test result

• Symptoms or history of encephalopathy (Grade II or worse) within 4 weeks of study entry
• Clinical evidence of severe ascites requiring intervention
• International normalized ratio (INR) >2.5
• Any evidence of progressive liver disease within the last 3 weeks prior to the screening visit) as indicated by worsening of clinical manifestations (i.e.: ascites, encephalopathy) and/or laboratories abnormalities (liver transaminases, alkaline phosphatase and GGT or a ≥ 50% worsening of serum bilirubin or prothrombin time)
• History of surgical portosystemic shunt with complications (i.e. hepatic encephalopathy, heart failure)
• Active bleeding during the last 28 days prior to dosing including variceal bleeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

DaVita Clinical Research-Denver

Lakewood, Colorado, United States

Clinical Pharmacology of Miami (CPMI)

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

DaVita Clinical Research

Minneapolis, Minnesota, United States

Kansas City Research Institute, LLC

Kansas City, Missouri, United States

Countries

United States

References

Piscitelli J, Hahn E, Wollenberg L, Chavira R, Del Frari L, Reddy MB. Pharmacokinetics of Binimetinib in Participants with Hepatic Impairment. Clin Pharmacokinet. 2025 Aug;64(8):1217-1230. doi: 10.1007/s40262-025-01509-0. Epub 2025 Jun 23.

Reference Type: DERIVED

PMID: 40549341 (View on PubMed)

Other Identifiers

CMEK162A2104

Identifier Type: -

Identifier Source: org_study_id